Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis

Status unconfirmed · Not applicable

Conditions studied: Distal Lateral Subungual Onychomycosis, Onychomycosis

In brief

This is a Pre-IDE, prospective, multicenter, randomized, parallel-group, double-blind, vehicle- controlled study to evaluate safety and effectiveness of Nail Genesis DLSO Product for the treatment of DLSO compared with vehicle in infected great toenails in a total of 338 males and non-pregnant, non-lactating, females between 18 and 65 years of age (inclusive). Subjects will be randomized in a 2:1 ratio to receive either Nail Genesis DLSO Product or vehicle. Subject eligibility will be determined during a Screening assessment. Subjects will complete a 4week washout period after discontinuation of a topical product or a 12-month washout period after discontinuation of an oral product or light-based therapy prior to randomization. Eligible subjects will be randomized in a 2:1 ratio to receive Nail Genesis DLSO Product or vehicle, respectively. During the 52-week trial, study medication will be administered once daily to the target toenail for 48 weeks. A subject will be considered to have completed the study when he or she has completed the study assessments at Week 52. The 52-week visit is for follow-up safety assessments.

Key facts

Study ID

NCT06074315

Run by

Nail Genesis LLC

People needed

338

Starts

2023-10-01

Expected to finish

2025-01-01

Last updated by the study team

2023-12-08

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is male or female, and 18 to 65 years of age, inclusive.
• Subject has nail fungal infection of at least one great toenail (per visual assessment, positive KOH preparation, and positive dermatophyte culture).
• Subject has target toenail showing 20-50% involvement without matrix (lunula) involvement.
• Subject has 3 mm of unaffected nail (from proximal nail fold) on target toenail.
• Subject has target toenail thickness of 3 mm or less.
• Subject must be physically able to reach toes to clean, trim, and apply product to the target toenail.
• Subject is willing and available to return for study follow up.
• Subject or legal representative is able to understand and provide signed consent for participating in the study.
• Female subject of childbearing potential has negative urine pregnancy test.
• Females must be post-menopausal or must agree to use approved contraceptives (actions, de- vices or medications to prevent or reduce the likelihood of pregnancy) throughout the study (abstinence is NOT an accepted form of contraception).

You may not qualify if…

• Subject has known hypersensitivity or allergy to the product materials.
• Subject has negative KOH preparation or dermatophyte culture.
• Subject has dermatophytoma on target toenail.
• Subject is enrolled in another investigational drug, device, or product protocol that would interfere with this study.
• Subject is using other topical or pharmaceutical treatments for any nail conditions; a wash-out period of at least four weeks after discontinuation of a topical product or 12 months after discontinuation of an oral product or light-based therapy for treatment of nail fungus is required.
• Subject has history of immunosuppression and/or clinical signs indicative of possible immunosuppression.
• Subject with possible chronic disease, including: diabetes, psoriasis, immune deficiency (HIV), severe foot injury, chronic vascular disease, or in which delayed treatment (approved treatment) of DLSO for one year could present a significant health concern.
• Subject has presence of toenail infection other than dermatophytes on target toenail.
• Subject has any disease/condition that might cause toenail abnormalities or interfere with evaluation.
• Subject has had previous toenail surgery on target toenail.
• Subject is a pregnant or nursing female.
• Subject is an Investigator, Nail Genesis' personnel, or Nail Genesis' Scientific Advisory Board (SAB) members, or their immediate family.

Where it is running

• Clinical Trials Institute of Northwest Arkansas — Fayetteville, Arkansas, United States (enrolling)
• Catalina Research Institute, LLC — Montclair, California, United States (enrolling)
• Northern California Research — Sacramento, California, United States (enrolling)
• Metro Clinical Trials — San Bernardino, California, United States (enrolling)
• Doctors Research Network — South Miami, Florida, United States (enrolling)
• The Education & Research Foundation, Inc. — Lynchburg, Virginia, United States (enrolling)
• Rochester Clinical Research, LLC — Rochester, New York, United States (enrolling)
• DermResearch — Austin, Texas, United States (enrolling)
• West Houston Clinical Research Service — Houston, Texas, United States (enrolling)
• Minnesota Clinical Study Center — New Brighton, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.